Schwab Charles Investment Management Inc. Buys 53,821 Shares of Juno Therapeutics Inc (JUNO)
Schwab Charles Investment Management Inc. grew its stake in shares of Juno Therapeutics Inc (NASDAQ:JUNO) by 16.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 378,195 shares of the biopharmaceutical company’s stock after purchasing an additional 53,821 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Juno Therapeutics were worth $17,288,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Advisor Group Inc. lifted its stake in shares of Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 3,559 shares in the last quarter. QS Investors LLC acquired a new position in shares of Juno Therapeutics during the second quarter worth about $135,000. Finally, Wellington Shields & Co. LLC acquired a new position in shares of Juno Therapeutics during the third quarter worth about $202,000. Institutional investors own 71.49% of the company’s stock.
Shares of Juno Therapeutics Inc (JUNO) opened at $86.56 on Friday. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $9,880.00, a PE ratio of -25.53 and a beta of 3.42. Juno Therapeutics Inc has a fifty-two week low of $19.62 and a fifty-two week high of $86.76.
In related news, EVP Robert Azelby sold 1,816 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $44.96, for a total value of $81,647.36. Following the completion of the sale, the executive vice president now directly owns 70,832 shares of the company’s stock, valued at $3,184,606.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Hans Edgar Bishop sold 270,250 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now directly owns 2,772,679 shares of the company’s stock, valued at $128,014,589.43. The disclosure for this sale can be found here. Over the last three months, insiders sold 473,031 shares of company stock valued at $27,031,205. 15.08% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://theolympiareport.com/2018/02/23/schwab-charles-investment-management-inc-buys-53821-shares-of-juno-therapeutics-inc-juno.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.